A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

Clinical trial NCT03288545 · TERMINATED

Trial details

NCT number: NCT03288545
Sponsor: Astellas Pharma Global Development, Inc.
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Carcinoma, Transitional Cell Urinary Bladder Neoplasms Urologic Neoplasms Renal Pelvis Neoplasms Urothelial Cancer Ureteral Neoplasms Urethral Neoplasms

Start date: 2017-10-11
Primary completion: 2026-02-20
Enrollment: 348

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.